In early October, the FDA approved avacopan to treat anti-neutrophil cytoplasmic antibody associated vasculitis. Here are insights into the treatment’s risks and considerations.
Search results for: hospital
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?
Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.
FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
On Oct. 15, the U.S. Food & Drug Administration (FDA) approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in August 2017, is both biosimilar to and interchangeable with (i.e, may be substituted for) its reference product Humira (adalimumab) for Cyltezo’s approved uses. Cyltezo is the second interchangeable biosimilar…
Trial Pits Upadacitinib vs. Adalimumab for Psoriatic Arthritis
As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis factor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medicine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib…
Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care
Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…
Fall 2021’s Awards, Appointments & Announcements in Rheumatology
Jeffrey Siegel, MD, Assumes New Position as Director for New Office of Drug Evaluation Sciences at the FDA On Feb. 16, Jeffrey Siegel, MD, became the director of the recently created Office of Drug Evaluation Sciences at the U.S. Food & Drug Administration (FDA). The move, he says, “puts together many of the different things…
Case Report: Is It Castleman Disease, or Castleman-Like?
The difference between Castleman disease and Castleman-like disease may be subtle, but it comes with significant ramifications. Case Presentation This case involves a pregnant 19-year-old woman who presents over multiple hospitalizations with concerns for systemic lupus erythematosus and macrophage activation syndrome. At 36 weeks’ gestation, the patient’s weight had dropped from 215 lbs. to 170…
The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First
The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…
Revisionist History: Seat Belts & Resistance to Public Health Measures
Some were furious. State by state, laws were enacted to ensure compliance. In most states, the laws were accompanied by a modest fine, as an added incentive. By the time the laws were written, most understood they were based on good science and common sense. The potential to save lives and prevent tragedy was finally…
- « Previous Page
- 1
- …
- 67
- 68
- 69
- 70
- 71
- …
- 330
- Next Page »